Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Legislative Response to Heparin Crisis Begins to Take Shape

This article was originally published in PharmAsia News

Executive Summary

The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape
Advertisement

Related Content

User Fee Bill Puts Industry, U.S. FDA to Work On Global Supply Chain Risks
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
FDA Considers Using Third-Party Inspectors to Enhance Global Reach
U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
Advertisement
UsernamePublicRestriction

Register

SC078758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel